Viatris stock analysis
Viatris (1VTRS) Stock Price & Analysis
1VTRS Stock Chart & Stats
- Day’s Range
- EUR 18.17 - EUR 18.42
- 52-Week Range
- EUR 5.00 - EUR 23.00
- Previous Close
- EUR 17.29
- Volume
- N/A
- Average Volume (3M)
- 342
- Market Cap
- EUR 21.40B
- Enterprise Value
- EUR 32.03B
- Total Cash (Recent Filing)
- EUR 1.90B
- Total Debt (Recent Filing)
- EUR 13.58B
- Price to Earnings (P/E)
- ―
- Beta
- 0.42
- Next Earnings
- Mar 01, 2027 (Est.)
- EPS Estimate
- 0.54
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.23%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Consistently positive free cash flow provides Viatris with internally generated funding for debt service, dividends, reinvestment, and business development. This is particularly valuable because cash generation remains strong even while GAAP earnings are negative, supporting financial resilience over the next several quarters.
Higher-Margin Portfolio Growth
Growth in complex generics, injectables, respiratory medicines, and hormone patches can improve the mix beyond commoditized generics. The combination of strong demand and added patch capacity gives Viatris a more durable route to revenue and margin improvement in its U.S. business.
Pacira Strategic Expansion
The proposed Pacira acquisition would broaden Viatris into patent-protected, non-opioid pain medicines while adding commercial and development capabilities. If completed as planned, the transaction could strengthen the innovative portfolio, support revenue diversification, and provide identifiable cost synergies.
Bears Say
Persistent GAAP Losses
Ongoing GAAP losses and a multi-year revenue downtrend show that Viatris has not yet converted its operating platform into consistent bottom-line earnings. Although EBITDA and cash flow remain positive, continued losses can restrict balance-sheet flexibility and make long-term performance more dependent on execution.
Nashik Supply And Regulatory Disruption
The Nashik remediation creates a durable operational and regulatory overhang rather than a routine quarterly fluctuation. Manufacturing suspension has already affected Europe and emerging markets, and continued constraints could reduce product availability, pressure revenue, and require management resources until remediation is completed.
Product Exclusivity And Competition Pressure
Upcoming and recent loss-of-exclusivity events expose Viatris to generic competition and potential erosion in established-product revenue. This pressure is structurally important because it can offset pipeline launches and portfolio improvements, requiring continual replacement of products whose market protection is declining.
Viatris News
Viatris Updates Dymista Study in Chinese Adolescents: What Investors Should Know
Viatris, Inc. ($VTRS) announced an update on their ongoing clinical study. Study Overview: Viatris’ NCT07597473 study is officially titled “Multicenter, Phase 4, Single-Arm Clinical Trial to Evaluate Efficacy and Safety
1VTRS FAQ
What was Viatris’s price range in the past 12 months?
What is Viatris’s market cap?
When is Viatris’s upcoming earnings report date?
How were Viatris’s earnings last quarter?
Is Viatris overvalued?
Does Viatris pay dividends?
What is Viatris’s EPS estimate?
How many shares outstanding does Viatris have?
What happened to Viatris’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Viatris?
What is the TipRanks Smart Score and how is it calculated?
Viatris Stock Smart Score
Company Description
Viatris
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith
- Employees
- 30,000
- Website
- www.viatris.com
- Address
- Robert J. Coury Global Center, Canonsburg, PA, 15317, US
Viatris (1VTRS) Earnings & Revenues
1VTRS Company Deck
1VTRS Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Viatris reported solid Q3 and nine-month financial growth, raised 2026 guidance, highlighted accelerating North American growth, continued Greater China momentum, strong cash flow, substantial pipeline progress, and expected benefits from the proposed Pacira acquisition. These positives outweighed challenges from Nashik-related supply constraints, policy-driven China moderation, regional declines, competition, and upcoming loss-of-exclusivity impacts.
View all IT:1VTRS earnings summaries1VTRS Net sales Breakdown
- 64.45% Brands
- 35.55% Generics
1VTRS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 1 | 7 |
| Technical Analysis | 2 | 1 | 7 |
| Moving Averages | 12 | 0 | 0 |











